Summary of Stoke Therapeutics FY Conference Call Company Overview - **Company**: Stoke Therapeutics (NasdaqGS:STOK) - **Focus**: Development of treatments for Dravet syndrome and Autosomal Dominant Optic Atrophy (ADOA) Key Points on Dravet Syndrome - **Market Opportunity**: Approximately 35,000-40,000 patients in the core geographies (U.S., Japan, U.K., EU 4) with about 16,000 in the U.S. and a similar number in the EU 4 [85][86] - **Addressable Patients**: 6,000 patients are immediately addressable upon launch, with 4,000 being pediatric patients aged 18 and younger [85][86] - **FDA Interactions**: Ongoing discussions with the FDA regarding the potential success of the phase 3 study and the importance of the label for pricing and promotion [15][71] - **Clinical Data**: Phase 1, 2 studies show robust seizure reduction and improvements in cognition and behavior, with a focus on longitudinal data over a 5-year period [17][19][20] - **Primary Endpoint**: Seizure reduction at 26 weeks, with secondary endpoints including cognition and behavior assessed at 52 weeks [48][55] - **Vineland Assessment**: Statistical improvements observed in Vineland scores, indicating cognitive and behavioral benefits [23][25] Phase 3 Study (EMPEROR) - **Enrollment Status**: Approximately 160 patients enrolled in the U.S. and Europe, with completion expected in mid-2027 [26][27] - **Study Design**: Includes lumbar puncture sham control patients and additional cohorts for regulatory compliance [27][35] - **Powering of Study**: Designed for a 90% confidence level with a p-value of 0.01 for secondary endpoints, ensuring robust statistical significance [48][52] Pricing and Market Dynamics - **Pricing Strategy**: Aiming for a price reflective of the value provided by the treatment, potentially aligning with other genetically targeted disease-modifying treatments rather than traditional anti-seizure medications [103][105] - **Comparison with SPINRAZA**: Pricing expected to be in line with other ASOs like SPINRAZA, which is priced around $600 per dose [118][105] Autosomal Dominant Optic Atrophy (ADOA) - **Patient Population**: Approximately 13,000 patients in the U.S. and Europe, with a significant risk of legal blindness [127] - **Phase 1 Study**: Ongoing dose escalation study with initial dosing completed, aiming to demonstrate efficacy in improving eyesight [128][129] Additional Insights - **Long-term Development**: The treatment aims to provide more years of neurotypical development for children with Dravet syndrome, addressing both seizure control and cognitive development [20][71] - **Genetic Testing**: Increased access and utilization of genetic testing are expected to enhance patient identification, particularly in adults who may have been misdiagnosed [88][90] Conclusion - Stoke Therapeutics is positioned to address significant unmet needs in the treatment of Dravet syndrome and ADOA, with ongoing clinical studies and strategic planning for market entry and pricing. The company emphasizes the importance of robust clinical data to support its treatment's efficacy and market potential.

Core Insights - The BUTTERFLY study highlights the significant impact of Dravet syndrome on children's neurodevelopment and functioning, indicating a need for new disease-modifying treatments [1][3][5] Company Overview - Biogen Inc. is a leading biotechnology company focused on innovative science to develop new medicines and create value for shareholders [8] - Stoke Therapeutics specializes in RNA medicine aimed at restoring protein expression, with its lead candidate zorevunersen under evaluation for Dravet syndrome [10] Study Findings - The BUTTERFLY study involved children and adolescents aged 2 to 18, assessing the effects of Dravet syndrome on neurodevelopment over two years [2][7] - Results showed that neurodevelopment plateaued at approximately two years of age, leading to a widening gap compared to neurotypical peers [5] - Major motor seizure frequency increased by 10.6% over the study period, with an average of 14.3 seizures per 28 days at baseline [5] Disease Characteristics - Dravet syndrome is characterized by recurrent seizures and significant cognitive and behavioral impairments, primarily caused by mutations in the SCN1A gene [4][6] - Over 90% of patients continue to experience seizures despite treatment with available anti-seizure medicines, leading to a poor quality of life [4][6] Future Implications - The findings from the BUTTERFLY study provide a baseline for understanding the potential impact of future disease-modifying therapies for Dravet syndrome [3][5]

Summary of Stoke Therapeutics Conference Call Company Overview - **Company**: Stoke Therapeutics (STOK) - **Industry**: Biotechnology, specifically focusing on genetic medicine for rare diseases, particularly Dravet syndrome Key Points and Arguments 1. **Leadership Transition**: Ian Smith, the interim CEO, has been with Stoke for two years and was involved in significant milestones, including the Phase III study and a strategic alliance with Biogen [5][6] 2. **Phase III Trial Initiation**: The Phase III trial for Stoke's drug, sorvenusiran, has been initiated in the U.S. as of last week, marking a significant advancement for the company [7] 3. **Differentiation of Drug**: Sorvenusiran is positioned as a disease-modifying therapy for Dravet syndrome, targeting the root cause by upregulating NAV 1.1, which is crucial for cognitive and behavioral improvements beyond just seizure reduction [10][11] 4. **Market Opportunity**: The prevalence of Dravet syndrome is estimated at 35,000 to 40,000 patients in major countries, with 15,000 to 20,000 in the U.S. alone, indicating a significant market potential [17][18] 5. **Breakthrough Designation**: The drug has received breakthrough designation from the FDA, facilitating better discussions regarding its approval and potential labeling claims [19][21] 6. **Trial Design and Data Timeline**: The EMPEROR trial is a 52-week study with approximately 50 patients, focusing on seizure reduction as the primary endpoint and Vineland scores as a secondary endpoint, with data readout expected in the second half of 2027 [23][24] 7. **Cognitive and Behavioral Benefits**: Longitudinal data suggests that patients on sorvenusiran show continuous improvement in cognition and behavior, which is a key differentiator from existing treatments [11][29] 8. **Financial Position**: The company has a strong cash position, with approximately $300 million available, sufficient to fund operations through mid-2028 [64][65] 9. **Future Indications**: Stoke is exploring other haploinsufficient disease areas, including ADOA and Syngap, indicating a broader pipeline strategy [66][67] Additional Important Content - **Natural History Study**: A natural history study has been conducted, showing that untreated children with Dravet syndrome stabilize in growth and development around age two, highlighting the potential impact of treatment [31][33] - **Safety Profile**: No significant safety concerns have been reported in previous studies, with a high percentage of patients rolling over into the open-label extension study [60][63] - **Statistical Significance**: The study is powered to show statistical significance for both seizure reduction and Vineland scores, which are critical for labeling and market acceptance [36][39] This summary encapsulates the critical insights from the conference call, focusing on Stoke Therapeutics' strategic direction, product differentiation, market potential, and financial health.